Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 5/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3693911 | 0.97 | CFTR (0.49) | CFTRMEN1GAAKMT2AF10 | |
| SCHEMBL3699004 | 0.91 | CFTR (0.51) | CFTRMEN1GAAKMT2AF10 | |
| SCHEMBL3693915 | 0.88 | F10 (0.54) | CFTRMEN1GAAKMT2AF10 | |
| SCHEMBL13626549 | 0.81 | NAMPT (0.51) | CFTRMEN1GAAKMT2AF10 | |
| SCHEMBL13626550 | 0.81 | NAMPT (0.51) | CFTRMEN1GAAKMT2AF10 | |
| SCHEMBL13626504 | 0.81 | NAMPT (0.51) | CFTRMEN1GAAKMT2AF10 | |
| SCHEMBL13664671 | 0.80 | F10 (0.54) | CFTRMEN1GAAKMT2AF10 | |
| SCHEMBL13626564 | 0.80 | F10 (0.54) | CFTRMEN1GAAKMT2AF10 | |
| SCHEMBL13626560 | 0.80 | F10 (0.52) | CFTRMEN1GAAKMT2AF10 | |
| SCHEMBL13626502 | 0.79 | LMNA (0.58) | CFTRMEN1GAAKMT2AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | BOEHRINGER MARKUS (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F12, F11, F2 | CFTR 779/4885MEN1 191/4885GAA 2189/4885 |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | F12, F11, F2 | CFTR 779/4885MEN1 191/4885GAA 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.